Send to

Choose Destination
Curr Opin Pharmacol. 2008 Oct;8(5):627-31. doi: 10.1016/j.coph.2008.08.011. Epub 2008 Oct 4.

Antibody-based identification of cell surface antigens: targets for cancer therapy.

Author information

Raven Biotechnologies, Inc., One Corporate Drive, South San Francisco, CA 94080, USA.


The identification of novel cell surface antigens present on tumor cells is crucial for developing new cancer therapies. Intact, viable cancer cells, which display cancer-restricted antigens in their native conformation and cellular context, provide a rich source of novel antigens. Antibody-based technologies are being used to probe the surface of intact cancer cells for cancer-specific antigen targets. In addition to identifying new proteins, these approaches are generating monoclonal antibodies (MAbs) to cancer-specific epitopes and nonprotein targets not amenable to genomics-based approaches. The multiple cell-based approaches developing epitope-specific MAbs to cancer antigens is likely to usher in a new era of therapeutic MAb target discovery.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center